🌐 Entity
Orforglipron
Anti-obesity medication
📊 Rating
2 news mentions · 👍 0 likes · 👎 0 dislikes
📌 Topics
- Healthcare Accessibility (1)
- Digital Health Innovation (1)
- Pharmaceutical Pricing (1)
- Pharmaceuticals (1)
- Market Competition (1)
- Healthcare Access (1)
🏷️ Keywords
Foundayo (2) · GoodRx (1) · GLP-1 medication (1) · weight loss drugs (1) · telehealth (1) · affordable healthcare (1) · direct-to-consumer (1) · prescription access (1) · Eli Lilly (1) · weight loss pill (1) · GLP-1 agonist (1) · obesity drug (1) · FDA approval (1) · pharmaceutical market (1)
📖 Key Information
Orforglipron, sold under the brand name Foundayo, is an oral, non-peptide, small-molecule GLP-1 receptor agonist developed as a weight loss drug by Eli Lilly and Company. It was discovered by Chugai Pharmaceutical Co., then was licensed to Lilly in 2018.
Orforglipron was approved for medical use in the United States in March 2026.
📰 Related News (2)
🔗 Entity Intersection Graph
People and organizations frequently mentioned alongside Orforglipron:
-
🏢
GoodRx · 1 shared articles
-
Eli Lilly · 1 shared articles -
Food and Drug Administration · 1 shared articles